Molecular basis of familial and sporadic alzheimer’s disease

Current Alzheimer Research

Volumn 13, Issue 9, 2016, Pages 952-963

  Dorszewska, Jolanta ^a   Prendecki, Michal ^a   Oczkowska, Anna ^a   Dezor, Mateusz ^a   Kozubski, Wojciech ^b  

^a Laboratory of Neurobiology   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

DNA; FAD; Genetic and biochemical factors; RNA; SAD

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER A7; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; PRESENILIN 1; PRESENILIN 2; PROTEIN MTHFD1; TAU PROTEIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DNA DAMAGE; FAMILIAL ALZHEIMER DISEASE; GENETIC VARIABILITY; HUMAN; NEUROFIBRILLARY TANGLE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN METABOLISM; RISK FACTOR; SPORADIC ALZHEIMER DISEASE; ANIMAL; GENETICS; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; HUMANS;

EID: 84981488800     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160314150501     Document Type: Article

References (151)

1. Brickel KL, Steinbart EJ, Rumbaugh M, Payami H, Schellenberg GD, Van Deerlin V, et al. Early-onset Alzheimer disease in families with late-onset Alzheimer disease: A potential important subtype of familial Alzheimer disease. Arch Neurol 63: 1307-11 (2006).
2. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23: 213-27 (2010).
3. Sorbi S, Forteo P, Tedde A, Cellini E, Ciantelli M, Bagnoli S, et al. Genetic risk factors in familial Alzheimer’s disease. Mech Aging Dev 122: 1951-60 (2001).
4. Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: A genetic perspective. Cell 120: 545-55 (2005).
5. Zekanowski C, Wojda U. Aneuploidy, chromosomal missegregation, and cell cycle reentry in Alzheimer’s disease. Acta Neurobiol Exp 69: 232-53 (2009).
6. Lahiri DK, Maloney B, Basha MR, Ge YW, Zawia NH. How and when environmental agents and dietary factors affect the course ofAlzheimer’s disease: The "LEARn" model (latent early-life associated regulation) may explain the triggering of AD. Curr Alzheimer Res 4: 219-28 (2007).
7. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 82: 239-59 (1991).
8. Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science 314: 777-81 (2006).
9. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 115: 1449-57 (2005).
10. Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C, Sleegers K. SORL1 is geneticaly associated with increased risk for late-onset Alzheimer’s disease in the Belgian population. Hum Mutat 29: 769-70 (2008).
11. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90: 9649-53 (1993).
12. Steiner H, Capell A, Leimer U, Haass C. Genes and mechanisms involved in beta-amyloid generation and Alzheimer’s disease. Eur Arch Psych and Clin Neurol 249: 266-70 (1999).
13. Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer’s disease. Lancet Neurol 12: 92-104 (2013).
14. Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, et al. Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 65: 664-70 (1999).
15. Murakami K, Irie K, Morimoto A, Ohigashi H, Shindo M, Nagao M, et al. Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: Implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer’s disease. J Biol Chem 278: 46179-87 (2003).
16. Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 361: 1957-8 (2003).
17. Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Human Mut 33: 1340-1344 (2012).
18. Van Broeckhoven C. Presenilins and Alzheimer disease. Nat Genet 11: 230-2 (1995).
19. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis. Neurology 83: 253-60 (2014).
20. Raux G, Guyant-Marechal L, Martin C, Bou J, Penet C, Brice A, et al. Molecular diagnosis of autosomal dominant early onset Alzheimer’s disease: An update. J Med Genet 42: 793-5 (2005).
21. Rovelet-Lecrux A, Hannequin D, Raux G, Meur NL, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38: 24-6 (2006).
22. Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani, L, et al. Early onset Alzheimer’s disease caused by mutations at codon 717 of the b-amyloid precursor protein gene. Nature 353: 844-6 (1991).
23. Goate R, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349: 704-6 (1991).
24. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early onset familial Alzheimer’s disease. Nature 375: 754-60 (1993).
25. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 269: 973-7 (1995).
26. Guyant-Marechal I, Berger E, Laquerriere A, Rovelet-Lecrux A, Viennet G, Frebourg T, et al. Intrafamilial diversity of phenotype associated with APP duplication. Neurology 71: 1925-6 (2008).
27. Hooli BV, Mohapatra G, Mattheisen M, Parrado AR, Roehr JT, Shen Y, et al. Role of common and rare APP DNA sequence variants in Alzheimer disease. Neurology 78: 1250-7 (2012).
28. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, et al. Mutation of the Alzheimer’s disease amyloid gene in a hereditary cerebral hemorrhage, Dutch type. Science 248: 1124-6 (1990).
29. Peacock ML, Warren JTJr, Roses AD, Fink JK. Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer’s disease. Neurology 43: 1254-6 (1993).
30. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488: 96-99 (2012).
31. Guyant-Marechal L, Rovelet-Lecrux A, Goumidi L, Cousin E, Hannequin D, Raux G, et al. Variations in the APP gene promoter region and risk of Alzheimer disease. Neurology 68: 684-7 (2007).
32. Ting SK, Chong MS, Kandiah N, Hameed S, Tan L, Au WL et al. Absence of A673T amyloid-β precursor protein variant in Alzheimer’s disease and other neurological diseases. Neurobiol Aging 34: 2441.e7-8 (2013).
33. Bamne MN, Demirci FY, Berman S, Snitz BE, Rosenthal SL, Wang X, et al. Investigation of an amyloid precursor protein protective mutation (A673T) in a North American case-control sample of late-onset Alzheimer’s disease. Neurobiol Aging 35: 1779.e15-6 (2014).
34. Liu YW, He YH, Zhang YX, Cai WW, Yang LQ, Xu LY, et al. Absence of A673T variant in APP gene indicates an alternative protective mechanism contributing to longevity in Chinese individuals. Neurobiol Aging 35: 935.e11-2 (2014).
35. Carter DA, Desmarais E, Bellis M, Campion D, Clerget-Darpoux F, Brice A, et al. More missense in amyloid gene. Nat Genet 2: 255-6 (1992).
36. Kumar-Singh S, De Jonghe C, Cruts M, Cruts M, Kleinert R, Wang R, et al. Nonfibrillar diffuse amyloid deposition due to a g (42)-secretase site mutation points to an essential role for N-truncated Ab (42) in Alzheimer’s disease. Hum Mol Genet 9: 2589-2598 (2000).
37. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, et al. Mutation of the b-amyloid precursor protein in familial Alzheimer’s disease increases b-protein production. Nature 360: 672-4 (1992).
38. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y. Amyloid beta protein (Abeta) deposition: Abeta 42(43) precedes abeta 40 in Down syndrome. Ann Neurol 37: 294-9 (1995).
39. Tandon A, Rogaeva E, Mullan M, St George-Hyslop PH. Molecular genetics of Alzheimer’s disease: The role of beta-amyloid and the presenilins. Curr Opin Neurol 13: 377-84 (2000).
40. Moro ML, Giaccone G, Lombardi R, Indaco A, Uggetti A, Morbin M, et al. APP mutations in the A beta coding region are associated with abundant cerebral deposition of A beta 38. Acta Neuropathol 124: 809-21 (2012).
41. Sandbrink R, Zhang D, Schaeffer S, Masters CL, Bauer J, Förstl H, et al. Missense mutations of the PS-1/S182 gene in German earlyonset Alzheimer’s disease patients. Ann Neurol 40: 265-266 (1996).
42. Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer’s disease. Annu Rev Genomics Hum Genet 3: 67-99 (2002).
43. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Defi ciency of presenilin 1 inhibits the normal cleavage of amyloid precursor protein. Nature 391: 387-390 (1998).
44. Lleo A, Blesa R, Queralt R, Ezquerra M, Molinuevo JL, Peña-Casanova J, et al. Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. Arch Neurol 59: 1759-1763 (2002).
45. Baulac S, LaVoie MJ, Kimberly WT, Strahle J, Wolfe MS, Selkoe DJ, et al. Functional gamma-secretase complex assembly in Golgi/trans-Golgi network: Interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates. Neurobiol Dis 14: 194-204 (2003).
46. Janssen JC, Beck JA, Campbell TA, Dickinson A, Fox NC, Harvey RJ, et al. Early onset familial Alzheimer’s disease: Mutation frequency in 31 families. Neurology 60: 235-239 (2003).
47. Finckh U, Muller-Thomsen T, Mann U, Eggers C, Marksteiner J, Meins W, et al. High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Am J Hum Genet 66: 110-117 (2000).
48. Mattila KM, Forsell C, Pirttila T, Rinne JO, Lehtimäki T, Röyttä M, et al. The Glu318Gly mutation of the presenilin 1 gene does not necessarily cause Alzheimer’s disease. Ann Neurol 44: 965-967 (1998).
49. Steiner H, Haass C. Intramembrane proteolysis by presenilins. Nat Rev Mol Cell Biol 1: 217-224 (2000).
50. Loy CT, Schofield PR, Turner AM, Kwok JBJ. Genetics of dementia. The Lancet 383: 828-840 (2014).
51. Alonso Vilatela ME, López-López M, Yescas-Gómez P. Genetics of Alzheimer’s disease. Arch Med Res 43: 622-31 (2012).
52. International Genomics of Alzheimer’s Disease Consortium (IGAP) et al. Convergent genetic and expression data implicate immunity in Alzheimer’s disease. Alzheimers Dement S1552-5260: 02492-02493 (2014).
53. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease. Nat Genet 41: 192-198 (2009).
54. Poduslo SE, Huang R, Huang J, Smith S Genome screen of lateonset Alzheimer’s extended pedigrees identifies TRPC4AP by haplotype analysis. Am J Med Genet B Neuropsychiatr Genet 150B: 50-5 (2009).
55. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303: 1832-40 (2010).
56. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J-C, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43: 429-35 (2011).
57. Hinney A, Albayrak O, Antel J, Volckmar A-L, Sims R, Chapman J, et al. Genetic variation at the CELF1 (CUGBP, elav-like family member 1 gene) locus is genome-wide associated with Alzheimer’s disease and obesity. Am J Med Genet B Neuropsychiatr Genet 165B: 283-93 (2014).
58. Medway C, Morgan K. Review: The genetics of Alzheimer’s disease; putting flesh on the bones. Neuropathol Appl Neurobiol 40: 97-105 (2014).
59. Ruiz A, Heilmann S, Becker T, Hernández I, Wagner H, Thelen M, et al. Follow-up of loci from the International Genomics of Alzheimer’s Disease Project identifies TRIP4 as a novel susceptibility gene. Transl Psychiatry 4: e358 (2014).
60. Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, et al. GWAS of longitudinal amyloid accumulation on 18Fflorbetapir PET in Alzheimer’s disease implicates microglial activation gene IL1RAP. Brain 138: 3076-88 (2015).
61. Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 77: 43-51 (2015).
62. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45: 1452-1458 (2013).
63. Rosenthal SL, Bamne MN, Wang X, Berman S, Snitz BE, Klunk WE, et al. More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer’s disease risk. Neurobiol Aging 36: 2443.e21-6 (2015).
64. Hickman SE, El Khoury J. TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem Pharmacol 88: 495-8 (2014).
65. Jiang T, Yu J-T, Hu N, Tan M-S, Zhu X-C, Tan L. CD33 in Alzheimer’s Disease. Mol Neurobiol 49: 529-535 (2013).
66. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78: 631-43 (2013).
67. Ising C, Stanley M, Holtzman D. Current thinking on the mechanistic basis of Alzheimer’s and implications for drug development. Clin Pharmacol Ther 98: 469-71 (2015).
68. Hébert SS, Horré K, Nicolaï L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 105: 6415-20 (2008).
69. Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 280: 43224-35 (2005).
70. Goedeke L, Fernández-Hernando C. MicroRNAs: A connection between cholesterol metabolism and neurodegeneration. Neurobiol Dis 72: 48-53 (2014).
71. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer’s disease. Neuron 63: 287-303 (2009).
72. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 3: 89ra57 (2011).
73. Corder EH, Saunders AM, Strittmatter WJ, Schmechel D E, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261: 921-923 (1993).
74. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43: 1467-1472 (1993).
75. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90: 8098-8102 (1993).
76. Dorszewska J, Różycka A, Oczkowska A, Florczak-Wyspiańska J, Prendecki M, Dezor M, et al. Mutations of TP53 gene and oxidative stress in Alzheimer’s disease patients. Adv Alzheimers Dis 3: 24-32 (2014).
77. http://www.alzforum.org/mutations/search?genes[]=492& diseases[]=145&diseases[]=150&keywords-entry=&keywords=# results (date of access: 19-Sep-2015).
78. Kauwe JSK, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci USA 105: 8050-4 (2008).
79. Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol 101: 1371-8 (1985).
80. Bloom GS. Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71: 505-8 (2014).
81. Wilkaniec A, Czapski GA, Adamczyk A. CDK5 at crossroads of protein oligomerization in neurodegenerative diseases: Facts and hypotheses. J Neurochem 136: 222-33 (2016).
82. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. [Internet].. Proc Natl Acad Sci USA 91: 5562-6 (1994).
83. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261: 6084-9 (1986).
84. Arriagada P V, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42: 631-9 (1992).
85. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491-5 (2001).
86. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487-91 (2001).
87. King ME, Kan H-M, Baas PW, Erisir A, Glabe CG, Bloom GS. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol 175: 541-6 (2006).
88. Herrup K, Yang Y. Cell cycle regulation in the postmitotic neuron: Oxymoron or new biology? Nat Rev Neurosci 8: 368-78 (2007).
89. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, et al. Tau reduction prevents Abeta-induced defects in axonal transport. Science 330: 198 (2010).
90. Shipton OA, Leitz JR, Dworzak J, Acton CEJ, Tunbridge EM, Denk F, et al. Tau protein is required for amyloid-induced impairment of hippocampal long-term potentiation. J Neurosci 31: 1688-1692 (2011).
91. Seward ME, Swanson E, Norambuena A, Reimann A, Cochran JN, Li R, et al. Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer’s disease. J Cell Sci 126: 1278-86 (2013).
92. Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, Mandelkow E, et al. Amyloid-β oligomers induce synaptic damage via Taudependent microtubule severing by TTLL6 and spastin. EMBO J 32: 2920-37 (2013).
93. Leroy K, Ando K, Laporte V, Dedecker R, Suain V, Authelet M, et al. Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. Am J Pathol 181: 1928-40 (2012).
94. Tan M-S, Yu J-T, Tan L. Bridging integrator 1 (BIN1): Form, function, and Alzheimer’s disease. Trends Mol Med 19: 594-603 (2013).
95. Moreau K, Fleming A, Imarisio S, Lopez Ramirez A, Mercer JL, Jimenez-Sanchez M, et al. PICALM modulates autophagy activity and tau accumulation. Nat Commun 5: 4998 (2014).
96. Zhou Y, Hayashi I, Wong J, Tugusheva K, Renger JJ, Zerbinatti C. Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer’s disease. PLoS One 9: e103187 (2014).
97. Sottejeau Y, Bretteville A, Cantrelle F-X, Malmanche N, Demiaute F, Mendes T, et al. Tau phosphorylation regulates the interaction between BIN1‘s SH3 domain and Tau’s proline-rich domain. Acta Neuropathol Commun 3: 58 (2015).
98. Lahiri DK, Maloney B, Zawia NH. The LEARn model: An epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14: 992-1003 (2009).
99. Bihaqi SW, Schumacher A, Maloney B, Lahiri DK, Zawia NH. Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): Towards a new paradigm. Curr Alzheimer Res 9: 574-588 (2012).
100. Yu L, Chibnik LB, Srivastava GP, Pochet N, Yang J, Xu J, et al. Association of Brain DNA Methylation in SORL1, ABCA7, HLADRB5, SLC24A4, and BIN1 With Pathological Diagnosis of Alzheimer Disease. JAMA Neurol 72: 15-24 (2015).
101. Dorszewska J, Florczak J, Rozycka A, Kempisty B, Jaroszewska-Kolecka J, Chojnacka K, et al. Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer’s and Parkinson’s diseases. Acta Neurobiol Exp (Wars) 67: 113-129 (2007).
102. Lahiri DK, Maloney B. The "LEARn" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer’s disease, and proposes remedial steps. Exp Gerontol 45: 291-6 (2010).
103. Prusiner SB Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336: 1511-3 (2012).
104. Jaunmuktane Z, Mead S, Ellis M, Wadsworth JDF, Nicoll AJ, Kenny J, et al. Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature 525: 247-250 (2015).
105. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al. Exogenous induction of cerebral betaamyloidogenesis is governed by agent and host. Science 313: 1781-4 (2006).
106. Ridley RM, Baker HF, Windle CP, Cummings RM. Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm 113: 1243-51 (2006).
107. Stöhr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, et al. Purified and synthetic Alzheimer’s amyloid beta (Aβ) prions. Proc Natl Acad Sci USA 109: 11025-30 (2012).
108. Nussbaum JM, Seward ME, Bloom GS. Alzheimer disease: A tale of two prions. Prion 7: 14-19 (2013).
109. Zhang W, Bai M, Xi Y, Hao J, Liu L, Mao N, et al. Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: Involvement of oxidative stress and cholinergic dysfunction. Free Radic Biol Med 52: 1443-52 (2012).
110. Nath S, Agholme L, Kurudenkandy FR, Granseth B, Marcusson J, Hallbeck M. Spreading of neurodegenerative pathology via neuronto-neuron transmission of β-amyloid. J Neurosci 32: 8767-77 (2012).
111. Lahiri DK. Prions: A piece of the puzzle? Science 337: 1172 (2012).
112. http://www.mirbase.org/cgi-bin/query.pl?terms=hsa-mir (date of access 26-Sep-2015).
113. Prendecki M, Dorszewska J. The role of MicroRNA in the pathogenesis and diagnosis of neurodegenerative diseases. Austin Alzheimers Parkinsons Dis 1: 1-10 (2014).
114. Liu CG, Song J, Zhang YQ, Wang PC. MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer’s disease. Mol Med Rep 10: 2395-2400 (2014).
115. Vilardo E, Barbato C, Ciotti M, Cogoni C, Ruberti F. MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons. J Biol Chem 285: 18344-51 (2010).
116. Long JM, Lahiri DK. MicroRNA-101 downregulates Alzheimer’s amyloid-β precursor protein levels in human cell cultures and is differentially expressed. Biochem Biophys Res Commun 404: 889-95 (2011).
117. Long JM, Ray B, Lahiri DK. MicroRNA-153 physiologically inhibits expression of amyloid-β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem 287: 31298-310 (2012).
118. Patel N, Hoang D, Miller N, Ansaloni S, Huang Q, Rogers JT, et al. MicroRNAs can regulate human APP levels. Mol Neurodegener 3: 10 (2008).
119. Hébert SS, De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci 32: 199-206 (2009).
120. Delay C, Calon F, Mathews P, Hébert SS. Alzheimer-specific variants in the 3‘UTR of Amyloid precursor protein affect microRNA function. Mol Neurodegener 6: 70 (2011).
121. Schonrock N, Matamales M, Ittner LM, Gotz J. MicroRNA networks surrounding APP and amyloid-beta metabolism--implications for Alzheimer’s disease. Exp Neurol 235: 447-54 (2012).
122. Kiko T, Nakagawa K, Tsuduki T, Furukawa K, Arai H, Miyazawa T. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease. J Alzheimers Dis 39: 253-59 (2014).
123. Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, et al. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer’s disease, inhibits bcl2 translation. Brain Res Bull 80: 268-73 (2009).
124. Zhao Y, Bhattacharjee S, Jones BM, Dua P, Alexandrov PN, Hill JM, et al. Regulation of TREM2 expression by an NF-кB-sensitive miRNA-34a. Neuroreport 24: 318-23 (2013).
125. Bhatnagar S, Chertkow H, Schipper HM, Yuan Z, Shetty V, Jenkins S, et al. Increased microRNA-34c abundance in Alzheimer’s disease circulating blood plasma. Front Mol Neurosci 7: 2 (2014).
126. Zovoilis A, Agbemenyah HY, Agis-Balboa RC, Stilling RM, Edbauer D, Rao P, et al. microRNA-34c is a novel target to treat dementias. EMBO J 30: 4299-4308 (2011).
127. Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol 14: R78 (2013).
128. Nelson PT, Wang WX. MiR-107 is reduced in Alzheimer’s disease brain neocortex: Validation study. J Alzheimers Dis 21: 75-9 (2010).
129. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, et al. The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 28: 1213-23 (2008).
130. Banzhaf-Strathmann J, Benito E, May S, Arzberger T, Tahirovic S, Kretzschmar H, et al. MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease. EMBO J 33: 1667-80 (2014).
131. Galimberti D, Villa C, Fenoglio C, Serpente M, Ghezzi L, Cioffi SMG, et al. Circulating miRNAs as Potential Biomarkers in Alzheimer’s Disease. J Alzheimers Dis 42: 1261-1267 (2014).
132. Tan L, Yu JT, Liu QY, Tan MS, Zhang W, Hu N, et al. Circulating miR-125b as a biomarker of Alzheimer’s disease. J Neurol Sci 336: 52-56 (2014).
133. Jiang W, Zhang Y, Meng F, Lian B, Chen X, Yu X, et al. Identification of active transcription factor and miRNA regulatory pathways in Alzheimer’s disease. Bioinformatics 29: 2596-2602 (2013).
134. Müller M, Kuiperij HB, Claassen JA, Küsters B, Verbeek MM. MicroRNAs in Alzheimer’s disease: Differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging 35: 152-158 (2014).
135. Zhu HC, Wang LM, Wang M, Song B, Tan S, Teng JF, et al. MicroRNA-195 downregulates Alzheimer’s disease amyloid-β production by targeting BACE1. Brain Res Bull 88: 596-601 (2012).
136. Long JM, Ray B, Lahiri DK. MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J Biol Chem 289: 5184-98 (2014).
137. Liu CG, Wang JL, Li L, Wang PC. MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer’s disease. Int J Mol Med 34: 160-166 (2014).
138. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 68: 10094-10104 (2008).
139. Postina R. A closer look at alpha-secretase. Curr Alzheimer Res 5: 179-86 (2008).
140. Augustin R, Endres K, Reinhardt S, Kuhn PH, Lichtenthaler SF, Hansen J, et al. Computational identification and experimental validation of microRNAs binding to the Alzheimer-related gene ADAM10. BMC Med Genet 13: 35 (2012).
141. Bonda, DJ, Lee HG, Camins A, Pallàs M, Casadesus G, Smith MA, et al. The sirtuin pathway in ageing and Alzheimer disease: Mechanistic and therapeutic considerations. Lancet Neurol 10: 275-279 (2011).
142. Adlakha YK, Khanna S, Singh R, Singh VP, Agrawal A, Saini N. Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXRα expression and cholesterol homeostasis. Cell Death Dis 4: e780 (2013).
143. Bhattacharjee S, Zhao Y, Lukiw WJ. Deficits in the miRNA-34aregulated endogenous TREM2 phagocytosis sensor-receptor in Alzheimer’s disease (AD); an update. Front Aging Neurosci 6: 116 (2014).
144. Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, et al. Alzheimer’s therapeutics targeting amyloid Beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PloS One 9: e111899 (2014).
145. Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, et al. Alzheimer’s therapeutics targeting amyloid Beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PloS One 9: e111898 (2014).
146. Menting KW, Claassen JA. β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease. Front Aging Neurosci 6: 165 (2014).
147. Wang Q, Xiao B, Cui S, Song H, Qian Y, Dong L, et al. Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD. Dis Model Mech 7: 1385-95 (2014).
148. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer’s disease. PloS One 5: e9979 (2010).
149. Richardson A, Galvan V, Lin AL, Oddo S. How longevity research can lead to therapies for Alzheimer’s disease: The rapamycin story. Exp Gerontol 68: 51-8 (2015).
150. Berk C, Paul G., Sabbagh M. Investigational drugs in Alzheimer’s disease: Current progress. Expert Opin Investig Drugs 23: 837-46 (2014).
151. Saito S, Ihara M. New therapeutic approaches for Alzheimer’s disease and cerebral amyloid angiopathy. Front Aging Neurosci 6: 290 (2014).